On November 4, 2026 Polaris Rx reported that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS (iberdomide), the first cereblon E3 ligase modulator (CELMoD) therapy approved by the U.S. Food and Drug Administration (FDA). ZENBEXUS is approved, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.1
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Multiple myeloma is a blood cancer of the plasma cells in the bone marrow. The American Cancer Society estimates about 36,000 Americans will be diagnosed in 2026, and about 10,850 will die from the disease. Most patients are 65 or older at diagnosis, with an average age of 69. Many patients see their cancer return or stop responding to treatment, making new options for relapsed disease critical.2
ZENBEXUS is the first drug in a new class called cereblon-modulating protein degraders. It is supplied in 0.75 mg and 1 mg strengths.1 The FDA granted ZENBEXUS accelerated approval on August 13, 2026, based on the Phase 3 EXCALIBER-RRMM trial, which compared the ZENBEXUS regimen (n=207) against daratumumab, bortezomib and dexamethasone (n=213). In the study, 41 percent of patients taking the ZENBEXUS combination reached a complete response with no detectable cancer cells, known as minimal residual disease (MRD)-negative complete response. It is the first new multiple myeloma drug approved by the FDA based directly on MRD. Continued approval may depend on confirmatory trial results.3
"Polaris Rx is proud to be among a select group of pharmacies extending access to ZENBEXUS, the first therapy of its kind for patients with relapsed multiple myeloma," said Eric Sredzinski, PharmD, Chief Strategy Officer of Polaris Rx. "Because ZENBEXUS is taken at home, our pharmacists and patient-support teams can help patients stay on track between clinic visits. We’re excited to help bring this new option to patients and the care teams who support them."
(Press release, PolarisRx, NOV 4, 2026, View Source [SID1234674237])